SeaStar Medical Shares Close at $2.19 as FDA News Remains Unverified
Key Facts
SeaStar Medical shares, listed under the ticker ICU, closed at $2.19 on Nov. 2, 2026, according to EL7 data. Interest in the company is tied to QUELIMMUNE, a device for children with sepsis-associated acute kidney injury. But the Nov. 3 announcement that post-approval study requirements had been met could not be verified through a reliable public source. It therefore cannot be confirmed that the U.S. Food and Drug Administration closed the follow-up requirements or that this removed a regulatory obligation from the company. The shares had closed at the stated price in the session before the date of the circulating news.
The company announced on March 5, 2026, that it had completed the required enrollment in the SAVE registry, saying the registry included 50 patients. It said it planned to report safety results to the FDA at day 28 after analyzing the data. The registry is tied to post-approval monitoring of the device, which allows patient data to be tracked after use. According to the company, completing enrollment was part of the study requirements. The enrollment announcement alone does not establish that the regulator accepted the results or closed the related obligations.
QUELIMMUNE received FDA approval under the Humanitarian Device Exemption in February 2024. The company said the clinical data supporting approval showed safety and potential benefit for this use. The device is used to treat children with acute kidney injury caused by sepsis or a septic condition, and is connected to a continuous renal replacement therapy circuit. It is also known as a selective cytopheretic device for pediatric use. The approval places the product on a regulatory pathway that allows its use for this purpose while specified post-approval monitoring continues.
The FDA says post-approval studies may be required when a device is approved under a Humanitarian Device Exemption to monitor continued safety and potential benefit. It also says failure to comply with any study requirement may be grounds for withdrawing approval. This means that an announcement that the requirements had been closed, if confirmed, would have regulatory significance for the study obligations, but would not by itself change the device’s approved-use description. The available information does not include reliable confirmation that a decision on this matter was issued on Nov. 3. The status of the SAVE registry requirements after the alleged announcement therefore remains unresolved here.
In a published FDA review, the surveillance registry protocol was amended in 2025, and the required sample size was reduced from 300 patients to 50. The review linked the change to lower use and the number of patients exposed to treatment. The agency said the latest progress report was received on June 1, 2026, and summarized post-approval surveillance data for 50 patients through day 28 after treatment. The original approval letter set May 30, 2026, as the study completion date and Aug. 31, 2026, for submission of the final report, with progress reports every 6 months. These dates outline the regulatory monitoring framework but do not in themselves confirm whether the study was subsequently closed.
Separately, SeaStar Medical announced on Oct. 22, 2026, results from an exploratory analysis comparing a group treated with the device with the historical KID group. Survival through day 90 was 65.1% in the QUELIMMUNE group, versus 47.4% in the comparison group, with a P value of P=0.043, according to the company. The primary analysis included 43 patients who received the device for more than one day, versus 196 patients in the KID group. These are company analysis results from an external comparison, not an independent FDA conclusion about the device’s effectiveness. They also relate to the analysis announced in October and do not verify the news in November about closure of the regulatory follow-up requirements.